Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping. When considering the Sarepta Therapeutics Inc stock dividend history, we have taken known splits into account, such that the SRPT dividend history is presented on a split-adjusted ("apples to apples") basis. Sarepta Therapeutics Inc dividend history is presented both in graphical/chart form, and as a SRPT dividend history data table along the right-hand column.
|
SRPT Stock Dividend HistoryThe SRPT dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable SRPT historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the SRPT dividend history record. Also see the SRPT stock dividend history data table along the right-hand column below. |
|
|
Strong Buy (3.50 out of 4) 59th percentile
(ranked higher than approx. 59% of all stocks covered)
Analysts' Target Price: SRPT Forecast Based on data provided by Zacks Investment Research via Quandl.com |